Conference Correspondent

The cherry blossoms were in bloom, and the Washington, DC, Convention Center was a bustling hive of activity during the 38th Annual Congress of the Oncology Nursing Society (ONS), held April 25-28, 2013. Read More ›

Significant distress frequently accompanies the diagnosis and treatment of cancer but is often overlooked and is rarely screened for, according to Jimmie C. Holland, MD, of Memorial Sloan-Kettering Cancer Center, New York. Read More ›

Whereas survivorship should be viewed as another stage in the cancer journey—the same as diagnosis and treatment—concerns related to surviving cancer have been largely neglected. Read More ›

Conversations with terminally ill patients about treatment options for end-of-life care often occur when the patient is in pain, heavily medicated, and quite ill—on average, just 1 month before the patient dies. Read More ›

A pproximately 2350 urologists, oncologists, surgeons, radiation oncologists, and other oncology healthcare professionals gathered in Orlando, Florida, to attend the 2013 Genitourinary Cancers Symposium. Read More ›

As we know, the American healthcare system is going through exorbitant changes, changes that will affect all providers and all stakeholders in the cancer care ecosystem. Read More ›

While branded and generic enoxaparin share many traditional characteristics of low-molecular-weight heparins (LMWHs), they differ in several parameters that are relevant to an antithrombotic effect, according to researchers from Loyola University Medical Center, Maywood, Illinois, who presented their findings at the 54th Annual Meeting of the American Society of Hematology. Read More ›

At the ASH plenary session, investigators showed that acute promyelocytic leukemia (APL), traditionally one of the deadliest hematologic malignancies, can be treated without chemotherapy. Read More ›

A wealth of abstracts were presented at the 54th Annual Meeting of the American Society of Hematology (ASH), held in Atlanta, Georgia, on December 8-11, 2012. More than 18,000 hematologists and other healthcare professionals from around the world gathered to discuss the latest clinical developments in research, therapies, and practice strategies. Attendees had the opportunity to review thousands of selected scientific abstracts. Following are some of the highlights from the ASH annual meeting. Read More ›

Updated findings from the pivotal phase 2 Ponatinib Ph+ ALL and CML Evaluation (PACE) trial found robust activity and sustained benefit for the investigational tyrosine kinase inhibitor ponatinib in heavily pretreated patients with accelerated or blast-phase chronic myeloid leukemia (CML) or Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). Read More ›